Hikma Pharmaceuticals: London Based Drug Maker, with 65% Potential Upside

London Based Drug Maker, with 65% Potential Upside. We believe that the market drove down this company to an irrational level, due to its exposure in MENA. A few catalysts are discussed, which can bring this undervalued company back to a more rational valuation. Business description and background: Hikma Pharmaceuticals PLC engages in the development,…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here